Skip to search formSkip to main contentSkip to account menu

Canarypox virus

Known as: Avipoxvirus clade B1, Canarypox, Canarypox viruses 
A poxvirus of the genus Avipoxvirus. Has been adapted as a cloning vector (canarypox vector) for use as a mammalian expression vector.
National Institutes of Health

Related topics

Related topics

5 relations
Canarypox virus Ag:PrThr:Pt:Ser:OrdCanarypox virus Ag:PrThr:Pt:Ser:Ord:IFaspects of radiation effectsphysiological aspects

Broader (1)

Poxviridae

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Humoral response and antiviral cytokine expression following vaccination of thoroughbred weanlings--a blinded comparison of commercially available vaccines.
2009
2009
HIV vaccine trial results--an opening for further research.
HIV-AIDS has emerged as an enormous, worldwide public health problem over the past 25 years. An estimated 33 million persons are… 
Highly Cited
2005
Highly Cited
2005
High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects.
BACKGROUND In clinical trials, canarypox ALVAC-human immunodeficiency virus (HIV) vaccines have been shown to elicit human HIV… 
Highly Cited
2004
Highly Cited
2004
Safety profile of recombinant canarypox HIV vaccines.
Highly Cited
2003
Highly Cited
2003
Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study.
In the first preventative human immunodeficiency virus (HIV) vaccine study to be carried out in Africa, 40 HIV-seronegative… 
2002
2002
Recombinant Canarypox Vaccine-Elicited CTL Specific for Dominant and Subdominant Simian Immunodeficiency Virus Epitopes in Rhesus Monkeys1
Since virus-specific CTL play a central role in containing HIV replication, a candidate AIDS vaccine should generate virus… 
Review
2001
Review
2001
Therapeutic vaccines against melanoma and colorectal cancer.
Highly Cited
2000
Highly Cited
2000
Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of…
Antibodies generated by candidate HIV-1 vaccines in a phase I clinical trial were assessed for neutralizing activity with a panel… 
1997
1997
Challenge of chimpanzees immunized with a recombinant canarypox-HIV-1 virus.
To evaluate the potential protective efficacy of a live recombinant human immunodeficiency virus type 1 (HIV-1) canarypox vaccine… 
Highly Cited
1996
Highly Cited
1996
Immunogenicity and protective efficacy of a human immunodeficiency virus type 2 recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys.
The efficacy of a recombinant human immunodeficiency virus (HIV) type 2 canarypox (ALVAC HIV-2) vaccine candidate given alone or… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)